Latest news with #MeenakshiNevatia
&w=3840&q=100)
Business Standard
17 hours ago
- Business
- Business Standard
Pfizer share price up 3% on rolling out this vaccine; key details inside
Pfizer share price: Pharmaceutical company Pfizer shares were in focus on Tuesday, August 12, 2025, with the stock rising up to 2.92 per cent to an intraday high of ₹5,188 per share. At 9:45 AM, Pfizer shares were trading 2.66 per cent higher at ₹5,175 per share. By comparison, BSE Sensex was trading 0.25 per cent higher at 80,802.18 levels. Why did Pfizer share price rise today? Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. Offering broader serotype coverage, the vaccine represents a major step forward in protecting against pneumococcal disease. PCV20 provides immunity against 20 clinically major serotypes that cause the majority of invasive and non-invasive pneumococcal infections. Meenakshi Nevatia, managing director, Pfizer India, said, 'We are excited to launch PCV20, our 20-valent pneumococcal conjugate vaccine, in India. We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country.' Additionally, it will be available as a single-dose vaccine, potentially eliminating the need for a second shot, and is suitable for all adults, including those with chronic health conditions, the company revealed, in a statement. Adults over 50, along with individuals suffering from comorbidities such as asthma, COPD, chronic kidney disease, and diabetes, are at higher risk of contracting pneumococcal infections, which can lead to serious complications, hospitalisations, or death. Timely immunisation is considered crucial to lowering these risks. Pneumococcal conjugate vaccines are among the most effective public health measures for reducing the incidence and severity of pneumococcal disease. The launch of PCV20 in India reinforces Pfizer's 25-year track record in pneumococcal vaccine innovation and its ongoing commitment to preventive healthcare. About Pfizer Pfizer is a globally recognised biopharmaceutical company with a legacy spanning more than 170 years. Headquartered in New York City, the company is dedicated to discovering, developing, and delivering medical breakthroughs that improve lives. With operations in over 125 countries, Pfizer plays a critical role in advancing global health through a diverse range of innovative treatments and vaccines. In India, Pfizer has a strong presence, including a state-of-the-art manufacturing facility in Goa that supports both local and international supply chains. The company's work spans key therapeutic areas such as vaccines, oncology, internal medicine, and rare diseases. Pfizer is a leader in vaccine development, notably using mRNA technology in its Covid-19 vaccine. Its oncology division focuses on cutting-edge cancer treatments, while internal medicine offerings address chronic conditions like diabetes and heart disease. Pfizer also invests in rare disease research and provides popular over-the-counter products like Advil, Nexium, Centrum, and ChapStick.
Time of India
a day ago
- Health
- Time of India
Pfizer launches next-gen vaccine for pneumococcal disease
Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose. Tired of too many ads? Remove Ads Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine ( PCV20 ) for adults in vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease , it said in a enables timely and proactive protection for all adults, including those living with chronic conditions, it will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said."We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI
Economic Times
a day ago
- Health
- Economic Times
Pfizer launches next-gen vaccine for pneumococcal disease
Synopsis Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose. Reuters Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. The vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease, it said in a statement. It enables timely and proactive protection for all adults, including those living with chronic conditions, it added. PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said. "We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI
News18
a day ago
- Health
- News18
Pfizer launches next-gen vaccine for pneumococcal disease
Agency: PTI New Delhi, Aug 11 (PTI) Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. The vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease, it said in a statement. It enables timely and proactive protection for all adults, including those living with chronic conditions, it added. PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said. 'We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI MSS MSS MR MR view comments First Published: August 11, 2025, 19:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
